CA
NZ
UK
AU
IND
US
● Intismeran is an individualized cancer vaccine Moderna is developing with Merck.
Adagene Inc. (NASDAQ:ADAG) closed Friday’s US session sharply lower, finishing at $2.06, down 14.17% on the day. The biotech company was among the session’s larger percentage decliners. No company-specific news tied to Adagene was confirmed for October 16, 2026, so the move is best …
Anavex Life Sciences Corp. (NASDAQ:AVXL) fell on Friday, October 16, 2026, closing at $1.31, a decline of 11.49% on the day. The biotechnology company dropped alongside the broader group in a session that was unfriendly to risk-sensitive health-care names. The move is best explained …
Conexeu Sciences Inc. (NASDAQ:CNXU), a regenerative-medicine company, closed Friday, October 16, 2026, at $3.06, down 22.53% on the day, a decline steep enough to rank the stock among the largest percentage losers in the US market. No company-specific news was confirmed for Conexeu during …
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), the synthetic-biology company, closed Friday, October 16, 2026, at $10.27, a decline of 12.67% on the session. The move lands squarely within one of the day’s clearest themes: a pronounced retreat from high-growth and biotechnology shares. There was no …
Shares of Evommune Inc. (NYSE:EVMN) ended Friday, October 16, 2026, among the day’s steepest decliners, closing at $5.17, a loss of 12.82%. The move came during a broadly negative US session in which risk appetite drained out of growth and early-stage names. There was …
Azenta (NASDAQ:AZTA) closed down 6.33% at $34.21 on Oct. 16, 2026, as investigation notices from law firms tied to the abrupt Aug. 22 resignation of chief executive John Marotta kept pressure on the stock. A regulatory filing on Aug. 24 about the departure was …
GeneDx (NASDAQ:WGS) closed down 9.73% at $63.39 on Oct. 16, 2026, as the stock gave back part of its recent gains. Market commentary pointed to profit-taking and company-specific volatility rather than weakness across the wider group, which was holding up better.
Omeros (NASDAQ:OMER) closed down 13.57% at $16.24 on Oct. 16, 2026, after the European Medicines Agency's CHMP issued a negative opinion on its marketing authorization application for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. The decision followed a re-examination of the …
Picard Medical (NYSE American:PMI) closed up 27.00% at $12.70 on Oct. 16, 2026, after a volatile, headline-driven session. Trading in the stock was halted for volatility on Oct. 15 after a 21% drop, and early moves on Friday swung between a decline of about …
Please wait processing your request...